



ISO 9001:2015 Certified



OFFICE OF THE MANAGING DIRECTOR  
**ASSAM MEDICAL SERVICES CORPORATION LIMITED**  
 Central Drug Ware House Campus, Patherquery, Narengi, Guwahati, Assam-781026  
 Email id: [md-amscl@assam.gov.in](mailto:md-amscl@assam.gov.in)

e-File No. : 545539/20449

From : Managing Director,  
 Assam Medical Services Corporation Limited

To : Celon Laboratories Pvt. Ltd.  
 Plot No.264, Patrika Nagar, Madhapur, Hyderabad-500081, Telengana, India

**Sub :** Firm Debarment Notice for default in supply of ordered essential drugs. {i.e. i.) Doxorubicine HCL Injection 50 mg/25 ml ii) Cytarabine Injection 500 mg, iii) Doxorubicine HCL Injection 10 mg/5 ml & iv) Glycopyrrolate Injection 0.2mg/ml}.

**Ref :**

1. Tender No.: NHM-43018/2022-PROC/AMSCL/ECF: 255581/150953, Dated.09/02/2023 & all relevant corrigendum notices issued against this tender.
2. The detail PO delivery status as on date as per DVDMs portal is placed at Annexure-A.
3. Purchase order issued from AMSCL vide P.O No. is placed at Annexure-A.
4. Notice cum Extension issued vide letter no. 545539/4532, dated : 30-08-2024 & 545539/5153, dated : 13-09-2024
5. Show-cause notice issued vide letter no.545539/8672, dated : 03-01-2025.
6. Notice cum Extension issued vide letter no. 545539/7874, dated : 22-01-2025.
7. Final Notice cum Extension issued vide letter no. 545539/19788, dated : 05-11-2025.
8. Product Debarment Notice for non supply of ordered essential drugs Doxorubicine HCL Injection 10 mg / 5ml and Glycopyrrolate Injection 0.2 mg/ml vide letter no.545539/11968, dated-20.03.2025
9. Product Debarment notice for default in supply of ordered essential drugs Doxorubicine HCL Injection 50 mg/25 ml & Cytarabine Injection 500 mg, vide letter no. 545539/20023, dated: 14.11.2025

Sir/Madam,

With reference to the subject cited above, I am to inform you that your company was awarded with the Purchase Orders against your agreement with AMSCL vide tender under reference at Pt.1 above. But due to your non-supply of essential drugs within the contractual delivery period (75 days from placing of PO), days with highest financial period (i.e., @2% of the value of delayed goods per week of delay or part thereof subject to a maximum of 10% of the total order value) and after passing the scope of supply against several delivery extensions with additional time period, initially 02 nos. of ordered drugs i.e. Doxorubicine HCL Injection 10 mg / 5ml and Glycopyrrolate Injection 0.2 mg/ml was debarred vide notice no.545539/11968, dated : 20-03-2025 for 5 (Five) years for non-completion of desired supply and again 02 nos. of ordered drugs Doxorubicine HCL Injection 50

mg/25 ml & Cytarabine Injection 500 mg was debarred vide order no- 545539/20023, dated:14.11.2025 for 5 (Five) years due to non-completion of desired supply.

As such as per the stated tender **Clause No. 5, “Terms & Conditions” Sub Clause-H**, “Debarment/Blacklisting for failure in execution of supply/non supply/default in supply”,

**Pt. no.(ii) "Firm Debarment", your company is here by blacklisted and debarred from participating in any tender by the TIA or procuring agency for 3 (three) years.**

The relevant clauses are as below:

**Pt. no.(ii) Firm Debarment:** The firm shall be blacklisted and debarred from participating in any tender by the TIA or procuring agency for 3 (three) years if the company is debarred for all the items (where it has RC-“Rate Contract” for less than 3 items) or at least 3 items (where it holds RC-“Rate Contract” for more than equal to 3 items).

Pt. no.(iii) Forfeiture of Performance Security: a) In case of Product debarment: In addition to product debarment the performance security deposited by the supplier for that particular product shall be forfeited and apportioned towards financial penalty. b) In case of Firm debarment: In addition to firm debarment the entire performance security deposited by the supplier shall be forfeited and apportioned towards financial penalty.

**Clause No.5, Sub Clause-M. Alternative Purchase:**

i. If the empaneled supplier fails to execute the supply within the stipulated time, AMSCL is at liberty to make alternative purchase of the items for which the Purchase Orders have been placed from any other sources (such as Public Sector undertakings at their rates, empaneled bidders, and bidders who have been technically qualified in the said bid) or in the open market even at higher rates at the risk and the cost of the supplier and in such cases AMSCL shall have every right to recover the cost and impose penalty, apart from termination of the contract for the default.

ii. In the event of making ALTERNATIVE PURCHASE, the supplier will be imposed penalty apart from forfeiture of Security Deposit. The excess expenditure over and above contracted prices incurred by AMSCL in making such purchases from any other source or from the open market shall be recovered from the Security Deposit or from any other money due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier or from his properties, as per rules.

This is for favour of your kind information.

Managing Director,  
Assam Medical Services Corporation Limited

Memo e File No: 545539/20450-59

Copy to the:

1. Commissioner & Secretary to the Govt. of Assam, H & FW Department & Chairman AMSCL for kind information.
2. Commissioner & Secretary to the Govt. of Assam, MERD for kind information
3. Mission Director, NHM, Assam for kind information.
4. Director of Medical Education, Assam for information.
5. Director of Health Services for information.
6. Executive Director, NHM, Assam for information.
7. Principal cum Chief Superintendent/Superintendent, all Medical Colleges for information.
8. Jt. DHS, all Districts for information.
9. DDSM-all Districts and M.O i/c & Pharmacist-all Medical Colleges and Admin Manager & Pharmacist & AMSCL State Store for information.
10. P.S to the Hon'ble Minister, H & FW for kind information to the Hon'ble Minister.

-e-signed-

Managing Director,  
Assam Medical Services Corporation Limited